MarketBeam.io Platform FDA-Ready Social Media Management for Life Sciences
From first post to final audit. MarketBeam helps pharmaceutical, biotechnology, medical device, and life sciences organizations manage social media compliance through AI-powered content checks, controlled MLR approval workflows, compliant publishing, adverse event monitoring, and audit-ready documentation.
Social Media Moves Fast. FDA Responsibilities Do Not Disappear.
Pharmaceutical and life sciences companies are expected to communicate product information accurately, responsibly, and consistently across every digital channel.
That responsibility applies whether content is published by a corporate brand account, an employee, an executive, an agency, a healthcare professional, a patient advocate, or a paid influencer.
MarketBeam embeds compliance controls directly into the social media workflow, helping teams identify potential issues before publication and maintain control after content goes live.
What Is FDA Social Media Compliance?
FDA social media compliance refers to the processes pharmaceutical, biotechnology, and medical device companies use to ensure that digital communications follow applicable U.S. Food and Drug Administration expectations.
For prescription drug promotion, the FDA’s Office of Prescription Drug Promotion (OPDP) evaluates whether promotional communications are truthful, balanced, adequately supported, and consistent with approved product labeling.
The Most Common FDA Social Media Risk Areas
Social media speeds up communications, but also multiplies regulatory exposure. Without centralized governance, compliance errors become common.
Unsupported Claims
Promotional content may create risk when it communicates efficacy, superiority, safety, convenience, or patient outcomes that are not adequately supported.
Missing Risk Info
A post may emphasize product benefits while omitting important safety information, contraindications, warnings, or limitations.
Inadequate Fair Balance
Fair balance requires benefit information and risk information to be presented with appropriate prominence, layout, and readability.
Off-Label Promotion
Content may create regulatory risk when it suggests a use, population, dosage, outcome, or treatment context outside the approved label.
Version Control Errors
Last-minute edits, shortened captions, altered images, or missing disclosures can lead to publishing a different version than the MLR-approved one.
Platform Truncation
Important safety information may be hidden, truncated, separated from benefit claims, or rendered differently across dynamic social feeds.
Employee Advocacy
Employees may unintentionally modify approved content, add personal claims, use outdated material, or omit required disclosures.
Influencer Marketing Risk
Influencers, creators, and advocates may publish content that lacks adequate FDA disclosures, risk details, or approved brand messaging.
Adverse Event Exposure
Patients discussing side effects, complaints, or problems in comments require fast, structured identification and pharmacovigilance escalation.
Real-World Social Media Warnings
FDA's Office of Prescription Drug Promotion (OPDP) actively monitors and issues warning letters to life sciences companies for misleading digital marketing activities.
Sprout Pharmaceuticals, Inc.
The Office of Prescription Drug Promotion has reviewed promotional materials for Addyi (flibanserin). The Instagram post is false or misleading because it presents Addyi benefits but entirely omits the Boxed Warning regarding severe hypotension and syncope risks...
CEO Instagram post promoted Addyi® benefits while omitting safety warnings.
FDA Citation: Omitted severe hypotension Boxed Warning and made unapproved "sex pill for women" claims.
ImmunityBio, Inc.
The Office of Prescription Drug Promotion has reviewed promotional materials for ANKTIVA. The TV advertisement and podcast episode are false or misleading because they promote unapproved uses as a cancer vaccine for all cancers and failed to submit materials under FDA Form 2253...
Executive podcast and TV ad promoted therapy without regulatory filing.
FDA Citation: Indicated bladder cancer drug was a "cancer vaccine" and failed to submit FDA Form 2253 records.
Duchesnay Inc. (Kardashian)
The Office of Prescription Drug Promotion has reviewed promotional materials for Diclegis. The sponsored influencer Instagram post by Kim Kardashian is false or misleading because it communicates efficacy claims but fails to provide any risk warnings or fair safety balance...
Sponsored influencer Instagram post promoted drug without safety balance.
FDA Citation: Omitted all side effects, warning risks, and limitations of use, presenting an unbalanced layout.
Sanofi & Viatris
The Office of Prescription Drug Promotion has reviewed Beyfortus emails (Sanofi) and TOBI Podhaler DTC TV ads (Viatris). The materials are misleading because they overstate approved product indications and fail to present necessary risk and safety disclosures...
Misleading claims in email promotions and direct-to-consumer TV ads.
FDA Citation: Sanofi overstated RSV prevention scope, while Viatris DTC television ads overstated efficacy.
What Can Happen Without a Controlled Workflow?
Compare the fragmented, risky process used by marketing agencies against MarketBeam's unified compliance engine.
Content Drafted by Agency
Content created in silos via spreadsheets, emails, and shared documents.
Agency Revises the Message
Edits are made directly on drafts without version-control checks.
MLR Reviews an Outdated Version
Reviewers comment on a PDF draft that does not match the actual publish file.
A Different Version is Published
Last-minute caption changes occur directly in scheduling tool, leaving risk information missing.
Unmonitored Comments & Side Effects
A patient reports a side effect in comments. The community manager misses it, and it goes unescalated.
Audit Trail Failure
The organization cannot reproduce history during audit, resulting in regulatory action.
1. Content Creation
Draft social content, campaigns, and creatives directly in a collaborative, workspace dashboard built specifically for compliance parameters.
2. AI Regulatory PreCheck
Evaluate messaging against clinical claims, warnings, off-label keywords, character limits, and image text layouts before sending to MLR.
3. Medical, Legal, & Regulatory (MLR) Review
Structured parallel review streams based on product brand guidelines, avoiding fragmented email lists and comment errors.
4. Expiration & Approval Signoff
Lock the final copy and visual assets, assign explicit expiration boundaries, and output status records.
5. Direct Secure Publishing
Connect live scheduling arrays directly to approved asset codes. Restricted publishing guards prevent unapproved versions.
6. Adverse Event & Sentiment Triage
Continuously scan live comments, direct messages, and brand mentions for patient feedback, side-effects, and quality complaints.
7. Full Regulatory Audit Reports
Maintains absolute compliance trails mapping dates, edits, comments, approvals, and live publishing links for OPDP review.
MarketBeam AI Compliance Architecture
This infographic illustrates the MarketBeam AI Compliance Engine, an intelligent platform that enables compliant social media communication for life sciences organizations by combining internal business knowledge with external regulatory guidance.
Policies
Bodies
Policies
AI
Veeva Vault PromoMats Integration
For organizations using Veeva Vault PromoMats, MarketBeam bridges approved medical assets with social media scheduling. Reduce duplicate uploads, synchronize claim libraries, track asset expirations, and maintain digital version integrity.
MLR Approval Workflows
Route assets dynamically based on therapeutic area, market channels, or campaign risk.
Employee Advocacy
Unlock safe sharing: employees distribute pre-approved messages without altering compliance details.
Influencer Governance
Track sponsored creator copy, disclosures, dynamic campaign timelines, and approval status.
FDA Form 2253 Support
Assemble historical approval packages, dates, and creatives automatically for FDA submission.
Adverse Event & Complaint Monitoring
Every comment matters. AI-driven social listening flags potential patient side effects and complaints, feeding them directly into your safety workflow.
Also Monitors Product Quality Complaints
Social comments are also evaluated for packaging damage, broken delivery items, labeling discrepancies, storage conditions, or product malfunctions, ensuring regulatory safety requirements are met across the board.
Reduce Risk Across the Entire Content Lifecycle
MarketBeam embeds compliance control points directly into the social workflow, replacing fragmented tracking with locked records.
| Content Stage | Without MarketBeam | With MarketBeam |
|---|---|---|
| Claims | High-Risk Language
Writers and external agencies may use unsupported, unapproved, or outdated efficacy claims. | AI PreCheck Alignment
Instant scans catch exaggeration and check proposed claims against approved reference catalogs. |
| Fair Balance | Mismatched Prominence
Benefit statements are highlighted while safety disclosures are minimized or separated. | Structural Warnings
AI analyzes contrast and proximity, ensuring benefit claims are balanced with necessary risks. |
| MLR Review | Fragmented Emails
Review cycles require massive manual spreadsheets, email chains, and disconnected PDF copies. | Centralized Engine
Routing rules direct assets to specific medical, legal, and regulatory leads inside a single platform. |
| Version Control | Mismatched Publishing
Last-minute scheduling changes create inconsistencies between approved and published versions. | Version-Locking Gate
The final approved asset is locked, connecting approval directly to live scheduler publishing. |
| Influencer Campaigns | Post-Pub Reviews
Influencer assets are published directly, lacking disclosures or MLR signoff reviews. | Pre-Pub Governance
Influencers submit materials through MarketBeam portals, gating posts until review parameters pass. |
Built for Companies Bringing New Products to Market
Commercialization teams launch campaigns under immense time pressure, managing agency content and executive visibility while labels and claims evolve. MarketBeam helps launch teams build regulatory control lines from day one:
Built for Established Pharmaceutical Companies
Large organizations manage thousands of digital posts across multiple brands, agencies, regions, and patient advocacy campaigns. MarketBeam delivers global governance and brand consistency:
Quantified Business Outcomes
Enable secure marketing outreach while accelerating compliance pipelines and protecting brand integrity.
Faster Compliance Reviews
Identify compliance issues before formal reviews, minimizing tedious revision loops and cycle delays.
Lower Regulatory Risk
Eliminate off-label posting, missing disclosures, version mismatches, and unauthorized edits.
Faster Safety Triage
Detect comments containing potential side effects automatically and assign cases to safety analysts.
Audit-Ready Records
Store full history lists of original drafts, editor notes, MLR approvals, and published links.
Scalable Commercialization
Launch campaigns and enter new therapeutic areas without redesigning workflows.
Unified Collaboration
Streamline communication paths between marketing teams, external agencies, and internal legal reviewers.
MarketBeam vs. Generic Social Media Management Platforms
Standard social scheduling platforms lack regulatory safety controls required for life sciences digital promotion.
| Capability | Legacy Social Media Management | MarketBeam |
|---|---|---|
| Organic Social Publishing | ||
| Multi-Channel Scheduling | ||
| Veeva PromoMats MLR Integration | ||
| AI Compliance Pre-Check | ||
| Approval-Gated Publishing | Requires Configuration | |
| FDA 2253 & Date of First Use Tracking | ||
| Adverse Event Detection & Routing | ||
| End-to-End Audit Trail & Approval History | Limited | |
| Unified Organic + Paid Compliance Workflow | ||
| Purpose-Built for Regulated Industries | Generic Platform |
Frequently Asked Questions
Get answers to common regulatory, system integration, and security questions.
Make FDA-Ready Social Media Part of Your Workflow
Stop managing compliance reviews through fragmented emails and spreadsheet logs. Elevate brand safety, streamline regulatory cycles, and protect patient communities.
